Answers are grounded in this paper and cite their sources.
Uncovers plasma protein patterns linked to critical-care outcomes, suggesting potential biomarkers for vulnerability.
Existing biomarker studies profile plasma during acute illness, leaving pre-illness proteomic susceptibility to critical care largely uncharacterised. We mapped the baseline proteomic architecture of critical-care outcomes in UK Biobank and tested for sex differences. We performed a proteome-wide association study of 2923 plasma proteins in 53,000 UK Biobank participants linked to Hospital Episode Statistics critical-care records, analysing three outcomes: ever critical-care exposure, prolonged critical care, and in-hospital death during a critical-care hospitalisation. Primary analyses used logistic regression; sensitivity analyses included Cox models, cross-validated LASSO, sex-interaction testing, and reverse-causation proxy analyses. Of 53,000 participants, 2986 had at least one critical-care episode. For ever critical-care exposure, 545 proteins survived Bonferroni correction, led by GDF15 (OR per SD 1.37, 95% CI 1.33–1.42, P = 2.82 × 10⁻68). In-hospital death yielded 18 Bonferroni-significant proteins, again led by GDF15. Prolonged critical care showed a markedly attenuated signal. Sex-interaction effects were predominantly stronger in women. An exploratory reverse-causation analysis yielded null estimates, indicating unresolved residual confounding. Baseline plasma proteins measured a median of more than 10 years before any critical-care episode were associated with later critical-care exposure and in-hospital death during a critical-care hospitalisation, with a biologically coherent pattern spanning stress-response, renal, epithelial, inflammatory, and tissue-remodelling pathways and a secondary female-predominant interaction signal among the leading proteins. The incremental discrimination over demographics (ΔAUC 0.040 on a 0.672 baseline) was modest but detectable over a > 10-year horizon. We interpret the signal as a cumulative-morbidity proteomic axis of critical-illness susceptibility rather than as validated isolated pre-morbid biomarkers; reverse-causation risk could not be excluded and external-cohort validation is required.
No takes yet. Share an insight, caveat, or question.
Ren et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: